

EP 187: Rethinking germline gene editing and revolutionizing women’s fertility with Helen O’Neill
May 15, 2025
Helen O’Neill, a molecular geneticist and founder of Hertility Health, chats about her unique insights into genetics sparked by being an identical twin. She shares her firsthand experience during the CRISPR baby controversy and discusses the persistent public skepticism around gene editing. O’Neill highlights her research on embryo viability through genetic screening and the potential for newborn genome sequencing to revolutionize early diagnosis. Additionally, she reveals how Hertility Health is transforming women’s access to fertility care.
AI Snips
Chapters
Transcript
Episode notes
CRISPR Baby Announcement Shock
- Helen O'Neill experienced the shock of the 2018 CRISPR baby announcement firsthand at a conference.
- She felt anger as the researcher bypassed thorough safety and ethical considerations she had planned to discuss.
Genome Editing Stalled by Perception
- Despite rapid genome editing advances, public debate rehashes old safety concerns.
- Media framing heavily influences public perception, often ignoring technological progress.
Genome Editing Could Rescue Embryos
- Not all genetic mutations respond equally to preimplantation genetic testing and embryo selection.
- Some IVF patients might benefit more from genome editing to rescue viable embryos than repeated cycles.